PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
23821376-0	2014	Lack of KRAS, NRAS, BRAF and TP53 mutations improves outcome of elderly metastatic colorectal cancer patients treated with cetuximab, oxaliplatin and UFT.	Tegafur	150-153	KRAS proto-oncogene, GTPase	Homo sapiens	8-12	
27089049-13	2016	Extended RAS (KRAS/NRAS) mutations are proposed as predictive indicators with respect to the efficacy of adjuvant UFT chemotherapy in patients with resected stage III colorectal cancer.	Tegafur	114-117	KRAS proto-oncogene, GTPase	Homo sapiens	14-18